World's Best Scientists 2026 revealed!
Philip F. Halloran

Philip F. Halloran

D-Index & Metrics

Medicine

D-Index
115
Citations
56724
World Ranking
4493
National Ranking
174

Research.com Recognitions

  • 2007 - Fellow of the Royal Society of Canada Academy of Science

Overview

Philip F. Halloran is affiliated with the University of Alberta in Canada and specializes primarily in the field of Medicine, with a focused emphasis on Transplantation and related subfields. Their research intersects significant clinical and biological aspects of organ transplantation, especially kidney transplantation.

Their work encompasses several subfields including:

  • Transplantation
  • Surgery
  • Epidemiology
  • Nephrology
  • Immunology

Philip F. Halloran has contributed extensively to topics such as:

  • Renal Transplantation Outcomes and Treatments
  • Transplantation: Methods and Outcomes
  • Organ Transplantation Techniques and Outcomes
  • Renal Diseases and Glomerulopathies
  • Viral Infections and Immunology Research
  • Organ Donation and Transplantation
  • Cytomegalovirus and herpesvirus research

Their publication record includes contributions to prominent journals such as Transplantation, American Journal of Transplantation, The Journal of Heart and Lung Transplantation, Journal of the American Society of Nephrology, and Transplant International.

Selected recent papers authored or co-authored by Philip F. Halloran include:

  • "Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes," 2022, American Journal of Transplantation
  • "The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics," 2023, American Journal of Transplantation
  • "A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection," 2020, Journal of the American Society of Nephrology
  • "CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection," 2020, Transplantation
  • "Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies," 2020, Journal of the American Society of Nephrology

Frequent collaborators include:

  • Katelynn S. Madill-Thomsen
  • Georg A. Böhmig
  • Martina Macková
  • Farsad Eskandary
  • Klemens Budde

Philip F. Halloran has been recognized as a Fellow of the Royal Society of Canada since 2007, under the Academy of Science category.

Best Publications

  • The Banff 97 working classification of renal allograft pathology

    Lorraine C. Racusen;Kim Solez;Robert B. Colvin;Stephen M. Bonsib

  • Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

    K. Solez;R. B. Colvin;L. C. Racusen;M. Haas

  • Reduced exposure to calcineurin inhibitors in renal transplantation.

    Henrik Ekberg;Helio Tedesco-Silva;Alper Demirbas;Štefan Vítko

  • Immunosuppressive Drugs for Kidney Transplantation

    Philip F. Halloran

  • International standardization of criteria for the histologic diagnosis of renal allograft rejection : the Banff working classification of kidney transplant pathology

    K.i.m. Solez;Roy A. Axelsen;Hallgrimur Benediktsson;James F. Burdick

  • Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.

    J. Sellarés;D. G. de Freitas;M. Mengel;J. Reeve

  • Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').

    K. Solez;R. B. Colvin;L. C. Racusen;B. Sis

  • Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

    Lorraine C. Racusen;Robert B. Colvin;Kim Solez;Michael J. Mihatsch

  • Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation

    F. Vincenti;R. Kirkman;S. Light;G. Bumgardner

  • The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials

    M. Haas;A. Loupy;C. Lefaucheur;C. Roufosse

  • Costimulation blockade with belatacept in renal transplantation.

    Flavio Vincenti;Christian Larsen;Antoine Durrbach;Thomas Wekerle

  • A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation

    Paul Keown;Pekka Häyry;Peter Morris;Calvin Stiller

  • Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups

    B. Sis;M. Mengel;M. Haas;R. B. Colvin

  • Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

    P Halloran;T Mathew;S Tomlanovich;C Groth

  • Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.

    G. Einecke;B. Sis;J. Reeve;M. Mengel

  • Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.

    Robert S. Gaston;J. Michael Cecka;Bert L. Kasiske;Ann M Fieberg

  • Rethinking chronic allograft nephropathy: the concept of accelerated senescence.

    Philip F. Halloran;Anette Melk;Claudia Barth

  • Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining.

    Banu Sis;Gian S. Jhangri;Sakarn Bunnag;Kara Allanach

  • Banff 2011 Meeting Report: New Concepts in Antibody‐Mediated Rejection

    M. Mengel;B. Sis;M. Haas;R. B. Colvin

  • The temporal profile of calcineurin inhibition by cyclosporine in vivo.

    Philip F. Halloran;Lisa M. H. Helms;Lina Kung;Jean Noujaim

Frequent Co-Authors

Michael Mengel
Michael Mengel University of Alberta
Bruce Kaplan
Bruce Kaplan University of Colorado Anschutz Medical Campus
Arthur J. Matas
Arthur J. Matas University of Minnesota
Lorraine C. Racusen
Lorraine C. Racusen Johns Hopkins University School of Medicine
Robert B. Colvin
Robert B. Colvin Harvard University
Mark D. Stegall
Mark D. Stegall Mayo Clinic
Joaquín Madrenas
Joaquín Madrenas University of California, Los Angeles
Jonathan S. Bromberg
Jonathan S. Bromberg University of Maryland, Baltimore
Richard N. Fedorak
Richard N. Fedorak University of Alberta

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine goes beyond traditional MD programs. Many students and professionals in the healthcare field are choosing flexible online degrees to advance their careers while managing other responsibilities.

For those interested in healthcare administration, it’s essential to look for which online healthcare degree programs are recognized for their accreditation by cahme? Accredited programs ensure quality education and can open doors to leadership roles.

Registered nurses seeking career advancement but aiming to avoid additional clinical requirements may consider rn to bsn with no clinicals programs. These options provide a faster pathway to a BSN and greater professional flexibility.

Advanced nursing degrees can further boost career opportunities. If you’re looking for efficiency, check out the shortest dnp programs. For those concerned about costs, there are also affordable dnp programs that make higher education more accessible.

These varied pathways highlight the range of options available for students and healthcare professionals seeking to expand their expertise and career potential in the U.S. medical field.

Best Scientists Citing Philip F. Halloran

Trending Scientists

Recently Published Articles